Europe Pharmacovigilance And Drug Safety Software Market Forecast, Regional Share And Growth Opportunity Analysis To 2031

(MENAFN- GlobeNewsWire - Nasdaq) ArisEurope, ICON, Syneos Health, Accenture, IQVIA, Genpact, Cognizant, Paraxel International, Laboratory Corporation of America, Max Application, Clinevo Technologies, Qinecsa Solutions, AB Cube and Veeva Systems are among the key European pharmacovigilance and drug safety software market players that are profiled in this market study.

Dublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "Europe Pharmacovigilance and Drug Safety Software Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Offering, Deployment, Enterprise Size, Form, Functionality, End User, and Country" report has been added to ResearchAndMarkets.com's offering.
The European pharmacovigilance and drug safety software market size was valued at US$ 52.37 million in 2023 and is forecast to reach US$ 84.66 million by 2031; it is estimated to record a CAGR of 6.2% from 2023 to 2031.

Cloud-based pharmacovigilance and drug safety software is likely to remain a key market trend.
Unlike traditional systems, cloud-based platforms offer real-time access to data from anywhere across Europe, enabling pharmaceutical companies to respond swiftly to emerging safety concerns. Cloud-based platforms enable real-time monitoring of adverse events that allow pharmaceutical companies to detect and respond to safety signals more quickly. With real-time data access, companies can generate safety reports on demand, significantly reducing the time required for decision-making. This immediacy is crucial in preventing adverse events from escalating into serious public health issues. Also, one of the most significant advantages of cloud-based drug safety solutions is their scalability.
As a company grows or as the volume of data increases, the cloud platform can scale accordingly without requiring additional infrastructure investments. This flexibility is particularly important in pharmacovigilance, where the volume of data can fluctuate significantly depending on the stage of the drug's lifecycle. Cloud-based systems are enabling the creation of global pharmacovigilance networks, where data can be shared across borders in real-time. These networks will enable more comprehensive drug safety monitoring, with insights and safety signals being shared worldwide, leading to faster identification and mitigation of risks.
Cloud-based platforms enable real-time monitoring of adverse events, permitting pharmaceutical companies to detect and respond to safety signals more quickly. With real-time data access, companies can generate safety reports on demand, significantly reducing the time required for decision-making. This immediacy is crucial in preventing adverse events from escalating into serious public health issues. Various companies offer cloud-based pharmacovigilance and drug safety software, such as Clinevo Technologies, Sarjen Systems and others. The cloud-based pharmacovigilance and drug safety software is expected to bring significant trends in the European pharmacovigilance and drug safety software market in the coming years.
The UK is witnessing advancements in the healthcare industry. The increased focus on digitizing healthcare and leveraging AI-powered analytics has fueled the adoption of pharmacovigilance and drug safety software in the country. Companies in the UK, including IQVIA, offer platforms that integrate AI and cloud solutions to improve real-time drug safety monitoring. These tools help organizations reduce the risks related to adverse reactions by using predictive analytics to preemptively identify potential issues, a critical feature in managing complex drug portfolios.
The Yellow Card Scheme is run by the Medicines and Healthcare Products Regulatory Agency (MHRA), where dentists, doctors, and hospital pharmacists are encouraged to report all serious suspected reactions to established medicines and suspected reactions to new medicines. In the UK, most doctors report directly to the National Regulatory Authority rather than pharmaceutical companies. In the UK, Good Pharmacovigilance Practice (GPvP) is the minimum standard required for monitoring the safety of medicines on sale to the public. Therefore, the abovementioned factors are expected to contribute to the pharmacovigilance and drug safety software market in the UK during the forecast period.
Based on form, the Europe pharmacovigilance and drug safety software market is segmented into standard and customized. The standard segment held the largest Europe pharmacovigilance and drug safety software market share. Standard pharmacovigilance and drug safety software refers to pre-configured, off-the-shelf solutions that provide a comprehensive set of tools designed to meet the general needs of drug safety monitoring.
This software offers essential features such as adverse event reporting, case management, signal detection, risk management, and regulatory compliance. Standard software are typically aligned with global pharmacovigilance regulations, such as those from the EMA, FDA, and ICH, making them suitable for a wide range of organizations. These software are mostly user-friendly and come with built-in templates, workflows, and automation capabilities to simplify safe data processing.
They are cost-effective and can be deployed relatively quickly. However, as the software is not tailored to specific needs, it might lack flexibility in handling unique processes or local regulatory requirements. A few examples of standard solutions include Oracle Argus Safety and Veeva Vault Safety, which cater to the broad requirements of most pharmaceutical and biotech companies.
ArisEurope, ICON, Syneos Health, Accenture, IQVIA, Genpact, Cognizant, Paraxel International, Laboratory Corporation of America, Max Application, Clinevo Technologies, Qinecsa Solutions, AB Cube and Veeva Systems are among the key European pharmacovigilance and drug safety software market players that are profiled in this market study.
Key Attributes:

Report Attribute	Details
No. of Pages	205
Forecast Period	2023 - 2031
Estimated Market Value (USD) in 2023	$52.37 Million
Forecasted Market Value (USD) by 2031	$84.66 Million
Compound Annual Growth Rate	6.2%
Regions Covered	Europe

Key Topics Covered:
1. Introduction
2. Executive Summary
2.1 Key Insights.
2.2 Market Attractiveness
3. Research Methodology
4. Europe Pharmacovigilance and Drug Safety Software Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 Software/Service Providers
4.3.2 System Integrators
4.3.3 Regulatory Bodies
4.3.4 End-Users
4.3.5 List of Vendors in the Value Chain

5. Europe Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
5.1 Europe Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
5.2 Market Drivers
5.2.1 Rise in Incidences of Adverse Drug Reactions
5.2.2 Globalization of Pharmacovigilance
5.2.3 Surge in Drug Development Rates
5.3 Market Restraints
5.3.1 High Installation and Maintenance Costs
5.4 Market Opportunities
5.4.1 Integration of Software with AI, ML, and NLP
5.5 Future Trends
5.5.1 Cloud-Based Pharmacovigilance and Drug Safety Software
5.6 Impact of Drivers and Restraints
6. Europe Pharmacovigilance and Drug Safety Software Market Analysis
6.1 Europe Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
6.2 Europe Pharmacovigilance and Drug Safety Software Market Forecast and Analysis
7. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Offering
7.1 Software
7.2 Services
8. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment
8.1 Cloud
8.2 On Premises
9. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size
9.1 Large Enterprises
9.2 SMEs
10. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Form
10.1 Standard
10.2 Customized
11. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality
11.1 Signal and Risk Management
11.2 Issue Tracking and Adverse Event Tracking
11.3 Case Management
11.4 Clinical Safety Management and Clinical Trial Safety
11.5 Quality and Compliance
11.6 Medical Writing
11.7 Audit Support and Training Compliance
11.8 Healthcare Analytics
11.9 Others
12. Europe Pharmacovigilance and Drug Safety Software Market Analysis - by End User
12.1 Pharmaceutical and Biotechnology Companies
12.2 Contract Research Organizations
12.3 Business Process Outsourcing (BPO) Firms
12.4 Others
13. Europe Pharmacovigilance and Drug Safety Software Market - Country Analysis
13.1 Europe
13.1.1 Europe Pharmacovigilance and Drug Safety Software Market
13.1.2 Europe Pharmacovigilance and Drug Safety Software Market Revenue and Forecast and Analysis - by Country.
13.1.2.1 Europe Pharmacovigilance and Drug Safety Software Market Revenue and Forecast and Analysis - by Country
13.1.2.3 France: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast to 2031 (US$ Thousand)
13.1.2.4 United Kingdom: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast to 2031 (US$ Thousand)
13.1.2.5 Italy: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast to 2031 (US$ Thousand)
13.1.2.6 Spain: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast to 2031 (US$ Thousand)
13.1.2.7 Rest of Europe: Europe Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast to 2031 (US$ Thousand)
14. Competitive Landscape
14.1 Heat Map Analysis by Key Players
14.2 Company Positioning & Concentration
15. Industry Landscape
15.1 Overview
15.2 Market Initiative
15.3 Merger and Acquisition
16. Company Profiles

• ArisGlobal
• Max Application
• Oracle Corp
• Veeva Systems
• IQVIA Holdings
• ICON
• Cognizant Technology Solutions Corp
• Accenture
• Syneos Health
• Genpact.
• AB Cube S.A.S.
• Laboratory Corp of America
• Parexel International
• Qinecsa Solutions
• Clinevo Technologies

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• European Pharmacovigilance and Drug Safety Software Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN27012025004107003653ID1109132184